Inorganic nanoparticles in diagnosis and treatment of breast cancer

被引:0
作者
Cristina Núñez
Sergio Vázquez Estévez
María del Pilar Chantada
机构
[1] Hospital Universitario Lucus Augusti (HULA),Research Unit, Oncology Division
[2] Servicio Galego de Saúde (SERGAS),Oncology Division
[3] Hospital Universitario Lucus Augusti (HULA),undefined
[4] Servicio Galego de Saúde (SERGAS),undefined
来源
JBIC Journal of Biological Inorganic Chemistry | 2018年 / 23卷
关键词
Breast cancer; Gold/magnetic nanoparticles; Quantum dots; Imaging; Therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Nanoparticles are being actively developed for biomolecular profiling of cancer biomarkers, tumor imaging in vivo, and targeted drug delivery. These nanotechnology-based techniques can be applied widely in the management of different malignant diseases, such as breast cancer. Although the number of different types of nanoparticles is increasing rapidly, most can be classified into two major types: particles that contain organic molecules as a major building material (such as dendrimers, micelles, liposomes and carbon nanotubes, and other polymers); and those that use inorganic elements, usually metals, as a core. In particular, inorganic nanoparticles have received increased attention in the recent past as potential diagnostic and therapeutic systems in the field of oncology. This review primarily discusses progress in applications of inorganic nanoparticles for breast cancer imaging and treatment.
引用
收藏
页码:331 / 345
页数:14
相关论文
共 811 条
[1]  
Siegel RL(2016)Breast cancer CA Cancer J Clin 65 7-30
[2]  
Miller K(2014)undefined J Cancer Sci Ther 6 099-104
[3]  
Jemal AJ(2011)undefined AJR Am J Roentgenol 197 W1023-W1030
[4]  
Kunnath AP(2004)undefined Br J Radiol 77 S194-S200
[5]  
Tiash S(2005)undefined Lancet 365 1727-1741
[6]  
Fatemian T(1982)undefined Histopathology 6 149-161
[7]  
Morshed M(2005)undefined Cancer Epidemiol Biomark Prev 14 1108-1112
[8]  
Mohamed SM(1994)undefined Cancer 73 1673-1677
[9]  
Chowdhury EH(1999)undefined J Natl Cancer Inst 91 2020-2028
[10]  
Geiser WR(2012)undefined Adv Drug Deliv Rev 54 631-651